Cellebrite DI: Positioned for Growth with Strategic Market Expansion and AI Integration

William Blair analyst Jonathan Ho has maintained their bullish stance on CLBT stock, giving a Buy rating on October 9.

Jonathan Ho has given his Buy rating due to a combination of factors that highlight Cellebrite DI’s potential for growth and market expansion. The company’s management has expressed optimism about a resurgence in 2026, supported by a strategic guidance reset and momentum in share performance. Additionally, there is a significant opportunity for Cellebrite to expand into adjacent markets, which could increase its total addressable market (TAM).
Furthermore, the recent Corellium deal, despite not being fully closed, has already started to contribute to the company’s TAM across defense, law enforcement, and private sector customers. The U.S. federal business, which contributes a substantial portion of annual recurring revenue, is expected to rebound, aided by the Department of Justice’s sponsorship of FedRAMP. This will allow broader access to Cellebrite’s platform. The company’s careful approach to integrating AI, ensuring data integrity with human oversight, also positions it well for future growth. Despite these positive indicators, the current stock price does not fully reflect the long-term growth potential across its product lines.

In another report released on October 9, Lake Street also reiterated a Buy rating on the stock with a $22.00 price target.